SK Biopharm’s Q3 sales rise 270% with rise in Xcopri sales
By | translator Alice Kang
22.11.10 10:13:06
가나다라
0
Company's Q3 sales record KRW 88.8 billion...Xcopri raises KRW 47.7 billion
Sees accelerated sales growth in the US... adopts aggressive marketing activities to increase prescriptions
Operating loss narrows to KRW 9.2 billion... cumulative losses amount to KRW 86.5 billion
On the 10th, SK Biopharmaceutical announced sales of KRW 88.8 billion in Q3 this year, a 270.9% on-year increase. The company also reported an operating loss of KRW 9.2 billion in the same period.
Almost half of its sales were driven by Xcopri. Xcopri generated sales of KRW 47.4 billion in the US in Q3 this year. This is over a twofold increase on-year from the KRW 19.9 billion it had generated in Q3 last year.
Xcopri’s sales have been driving the performance of the company after getting on track this year. After recording KRW 10 billi
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)